Table 3.
Overall survival stratified by risk factors
| Variable | Patient survival, % |
p value* | |||
|---|---|---|---|---|---|
| 1 y | 3 y | 5 y | 8 y | ||
| All patients | 75.6 (159) | 34.2 (58) | 18.2 (23) | 9.9 (9) | |
| Age, y | |||||
| <65 | 81.2 (78) | 36.8 (29) | 20.7 (12) | 11.4 (4) | 0.048 |
| ≥65 | 70.7 (80) | 31.9 (28) | 15.9 (10) | 8.7 (4) | |
| Sex | |||||
| Male | 80.8 (96) | 31.8 (32) | 17.8 (12) | 8.3 (4) | 0.687 |
| Female | 68.8 (62) | 37.0 (25) | 18.6 (10) | 12.2 (5) | |
| Margin status | |||||
| R0 | 77.7 (109) | 37.5 (39) | 23.6 (19) | 11.9 (7) | 0.056 |
| R1 | 71.4 (49) | 27.7 (18) | 8.4 (3) | – (1) | |
| Tumor size | |||||
| ≤2.5 cm | 73.2 (77) | 35.4 (30) | 21.3 (13) | 5.0 (2) | 0.744 |
| >2.5 cm | 79.3 (74) | 35.3 (26) | 17.3 (10) | 15.4 (8) | |
| Grade | |||||
| Well differentiated | 77.6 (31) | 42.6 (15) | 17.8 (4) | 0.0 (0) | 0.562 |
| Moderately/poorly differentiated | 73.7 (114) | 30.3 (36) | 17.8 (15) | 12.7 (7) | |
| AJCC stage | |||||
| Stage I & II | 79.3 (75) | 45.6 (32) | 27.7 (15) | 18.2 (7) | 0.001 |
| Stage III & IV | 68.5 (48) | 21.1 (11) | 5.8 (2) | 0.0 (0) | |
| AJCC T-stage | |||||
| T1–T2 | 74.6 (98) | 40.1 (39) | 24.3 (16) | 14.3 (6) | 0.008 |
| T3–T4 | 75.0 (25) | 15.3 (4) | 0.0 (0) | 0.0 (0) | |
| Lymph node metastases | |||||
| No | 80.3 (112) | 40.1 (45) | 22.7 (19) | 13.2 (9) | 0.001 |
| Yes | 66.2 (46) | 22.3 (12) | 8.7 (3) | 0.0 (0) | |
| Lymphovascular invasion | |||||
| No | 82.9 (80) | 41.7 (32) | 24.2 (14) | 6.1 (2) | 0.067 |
| Yes | 67.1 (45) | 26.1 (12) | 15.2 (5) | – (3) | |
| Perineural invasion | |||||
| No | 85.9 (34) | 47.8 (15) | 34.5 (10) | 21.6 (3) | 0.040 |
| Yes | 72.3 (102) | 29.8 (33) | 15.4 (14) | 5.9 (3) | |
Overall survival Kaplan–Meier estimates, the numbers provided are percentages of patients alive. Number of patients at risk is depicted between the parentheses. *p-value is determined using the Mantel–Haenszel test.